The fallopian tube is a complicated part when it comes to the female reproductive system. Not the least of these advances is the understanding that even tumors thought to originate in the ovary may actually originate in the fallopian tube. Although, in practice, we currently manage fallopian tube carcinomas similar to ovarian and primary peritoneal carcinomas, our growing understanding of the nuances of origin suggest that this may not always be the case—especially when we consider prevention strategies.
Most frequently, these predispositions are BRCA1 and BRCA2 mutations, but many other mutations may incur an increased risk.For patients with moderate-penetrance genes that are associated with increased cancer risk, such as BRIP1, RAD51C, and RAD51D, we provide counseling similar to that offered to women with BRCA1/2 mutations, and we recommend risk-reducing bilateral salpingo-oophorectomy.This is particularly important for patients with a diagnosis of fallopian tube cancer, in whom an increase in the incidence of BRCA1/2 mutations has been observed. Despite these clear recommendations, a large proportion (70% to 90%) of eligible women are not referred for genetic counseling and testing, and this group represents a significant unmet need in the care of women with fallopian tube and ovarian cancer.
We can say that with more awareness things are getting very much easier in fighting the fallopian cancer.